Sakar Healthcare reported a 120% year-on-year surge in profit after tax (PAT) to ₹1,028.49 lakhs for Q1FY27, while management outlined aggressive growth targets during the July 29, 2026, earnings call. The company aims to double its oncology division revenue to approximately ₹200 crore in FY27, up from roughly ₹93-94 crore in FY26. This expansion is driven by increasing export volumes, new marketing authorizations (MAs), and deeper integration with global partners like Accord-Intas, Torrent, and Zydus Lifesciences.

The Board of Directors approved the unaudited results on July 24, 2026. Consolidated revenue from operations rose 38% to ₹7,297.25 lakhs, with EBITDA jumping 67% to ₹2,124.89 lakhs. The improved profitability reflects better product mix and operating leverage. Management emphasized that the current facility at Bavla can support revenues of ₹800 crore to ₹1,000 crore at optimal utilization over the next four to five years without significant incremental capital expenditure.

Financial Performance Overview

Oncology Revenue and Export Growth

In Q1FY27, the oncology business generated approximately ₹33 crore, with exports contributing ₹6.5 crore and domestic sales making up the remainder. Management indicated that export contribution is expected to rise significantly, targeting ₹60-70 crore from exports alone in FY27. By FY28, oncology revenue is projected to reach ₹280-300 crore, representing a threefold increase over FY26 levels.

The company has executed more than 65 oncology product contracts and has 178 dossiers submitted globally, resulting in 16 MAs received so far. Seven site variation approvals have been secured for technology transfer projects with key partners. Bikramjit Ghosh, Vice President of Strategy and Business Development, noted that 70-75% of the incremental export revenue will come from MA-based sales, while the rest will stem from site variation products and CMO deals.

Margin Expansion via API Integration

A critical driver for future margin expansion is backward integration through in-house API development. Sakar has developed 21 APIs, with two already receiving CEP approvals (Gefitinib and Cytarabine) and five more in process. Management stated that integrating these APIs into finished dosage forms could push EBITDA margins to 35% or higher for those specific products. Currently, the overall EBITDA margin stands at 29%, up from 24% in Q1FY26, with non-oncology margins hovering around 25%.

What the Numbers Show

The divergence between the company’s total revenue growth (38%) and its oncology segment’s trajectory highlights a strategic pivot toward higher-margin, specialized pharmaceuticals. While the broader pharma market sees modest single-digit growth, Sakar’s oncology division is targeting double-digit annual growth rates. The reliance on exports is shifting from minimal contribution in previous quarters to a projected 30% share of total sales by end-FY27. This shift, combined with API backward integration, suggests a structural improvement in profit quality, moving away from pure contract manufacturing toward proprietary, high-value integrated supply chains.

Cobra India (Mauritius) Limited has acquired a 2.0462% stake in Sakar Healthcare Limited through open market transactions. The acquisition involved the purchase of 489,026 equity shares, increasing the acquirer's footprint in the pharmaceutical company. The disclosure was filed in compliance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the transaction on June 11, 2026, Cobra India (Mauritius) Limited held 1,469,571 shares, which accounted for 6.4532% of the total share or voting capital. Following the acquisition, the entity's holding adjusted to 980,545 shares, representing 4.4069% of the total share or voting capital. The acquirer clarified that it does not belong to the promoter or promoter group of the target company.

The total equity share capital and total voting capital of Sakar Healthcare Limited remained unchanged at INR 2,22,49,910 before and after the acquisition. The total diluted share or voting capital was also reported at INR 2,22,49,910. Cobra India (Mauritius) Limited stated that there were no warrants or convertible securities acquired as part of this transaction.

Acquisition Details

The filing provided a breakdown of the shareholding changes before and after the transaction:

The mode of acquisition was specified as an open market transaction. Jean-Marc Lesieur, Director of Cobra India (Mauritius) Limited, signed the disclosure submitted to the National Stock Exchange of India Ltd. The target company's shares are listed on the National Stock Exchange of India Limited.